IP Library Granted Patent US 9,422,531
Granted Patent B2
US 9,422,531 · App. 14/825,688 · Granted Aug 23, 2016

Biocatalysts for the preparation of hydroxy substituted carbamates

Inventors: Fabien Louis Cabirol (Dusseldorf, DE); Haibin Chen (Beijing, CN); Anupam Gohel (Bekasi, ID); Steven J. Collier (Concord, MA); Derek J. Smith (Singapore, SG); Birgit Kosjek (Westfield, NJ); Jacob Janey (New York, NY)
Assignee: Codexis, Inc.
C12N9/0006C12P13/00C12P13/001C12P13/02C12P41/002C12N15/70C12Y101/01184Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,531
App. No.
14/825,688
Granted
Aug 23, 2016
Kind
B2
Abstract

The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.

Claims (33)

1. An engineered polynucleotide encoding a ketoreductase polypeptide capable of converting substrate compound (2), tert-butyl(1-oxo-1-phenylhex-5-yn-2-yl)carbamate, to product compound (1), tert-butyl(1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate,

wherein the ketoreductase polypeptide comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:4 and comprises X40R and X206L or F, with the proviso that when X206 is F, the sequence further comprises one or more residue differences as compared to SEQ ID NO:4 selected from: X7S; X17M; X17Q; X17R; X23V; X27L; X29G; X60I; X64V; X71P; X87L; X94A; X94P; X94S; X95M; X96L; X96Y; X105G; X113I; X122A; X127R; X131S; X144V; X145L; X147I; X147L; X147Q; X150Y; X152G; X153G; X157C; X173L; X195A; X195G; X196M; X198S; X199H; X208R; X216R; X221S; X243S; X245I; X249F; X249G; and X249Y.

2. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of said ketoreductase polypeptide comprises X40R and X206F, and one or more residue differences as compared to SEQ ID NO:4 selected from: X7S; X17M; X17Q; X17R; X23V; X27L; X29G; X60I; X64V; X71P; X87L; X94A; X94P; X94S; X95M; X96L; X96Y; X105G; X113I; X122A; X127R; X131S; X144V; X145L; X147I; X147L; X147Q; X150Y; X152G; X153G; X157C; X173L; X195A; X195G; X196M; X198S; X199H; X208R; X216R; X221S; X243S; X245I; X249F; X249G; and X249Y.

3. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of said ketoreductase polypeptide comprises X40R and X206F or L, and at least one or more residue differences as compared to SEQ ID NO:4 selected from: X17Q/R/M; X64V; X94P; X144V; X147Q/I/L; X157C; and X196M.

4. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of said ketoreductase polypeptide comprises at least a combination of residue differences as compared to SEQ ID NO:4 selected from:

(a) X40R, X196M, and X206F/L;

(b) X40R, X144V, and X206F/L;

(c) X40R, X17H/R/Q, and X206F/L;

(d) X40R, X94P, and X206F/L;

(e) X40R, X196M, and X206F/L;

(f) X40R, X198S, and X206F/L;

(g) X40R, X17H/R/Q, X94P and X206F/L;

(h) X40R, X71P, X157C and X206F/L;

(i) X40R, X94P, X144V, X196M and X206F/L;

(j) X17H/R/Q, X40R, X64V, X147I/Q/L, and X206F/L;

(k) X17H/R/Q, X40R, X64V, X94P, X144V, X147I/Q/L, X157C, X196M and X206F/L; and

(l) X17Q, X40R, X64V, X71P, X94P, X144V, X147I, X157C, X196M, X206F, and X249F.

5. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide is capable of converting the substrate compound (2) to the product compound (1) with at least 10 fold the activity of the reference polypeptide of SEQ ID NO:4, wherein the amino acid sequence comprises the features X40R and X206L or F, and one or more residue differences as compared to SEQ ID NO:4 selected from: X60I; X71P; X94P; X94A; X95M; X96L; X96Y; X127R; X144V; X145I; X150Y; X152G; X153G; X157C; X195A; X195G; X196M; X198S; X199H; X206F, X216R, X245I, X245F; X249Y; and X249F.

6. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide has increased thermal stability as compared to the reference polypeptide of SEQ ID NO:4 or 32, wherein the amino acid sequence comprises the features X40R and X206L or F, and one or more residue differences as compared to SEQ ID NO:4 selected from: X17Q; X17R; X17W; X64V; X71P; X87L; X94S; X94P; X147Q; X147I; X147L; X157C, X198S; X249Y; and X249F.

7. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the ketoreductase polypeptide is capable of forming product syn-tert-butyl (1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate compounds (1a) and (1c)

in diastereomeric excess of anti-tert-butyl(1-hydroxy-1-phenylhex-5-yn-2-yl)carbamate compounds (1b) and (1d).

8. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 7 , wherein the amino acid sequence of the ketoreductase polypeptide comprises X40R and X206L of F, and one or more residue differences as compared to SEQ ID NO:4 selected from: X17Q; X64V; X71P; X87L; X147I; X157C; X196M; and X249F.

9. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 7 , wherein said ketoreductase polypeptide is capable of forming product compounds (1 a ) and (1c) in a diastereomeric ratio of at least 50 over compounds (1b) and (1d).

10. The engineered polynucleotide encoding the ketoreductase polypeptide of claim 1 , wherein the amino acid sequence of the ketoreductase polypeptide comprises a sequence selected from the group consisting of SEQ ID NO: 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170 and 172.

11. The polynucleotide of claim 1 , comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169 and 171.

12. An expression vector comprising the polynucleotide of claim 1 .

13. An expression vector comprising the polynucleotide of claim 11 .

14. The expression vector of claim 12 , comprising at least one control sequence.

15. The expression vector of claim 13 , in which the control sequence is a promoter.

16. A host cell comprising the polynucleotide of claim 11 .

17. The host cell of claim 15 , wherein said host cell is E. coli.

18. A method of preparing an engineered polypeptide comprising culturing the host cell of claim 16 , under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

19. A method of preparing an engineered polypeptide comprising culturing the host cell of claim 17 , under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (3)
Division 14357964
Provisional Application 61561665 · Nov 18, 2011
Related Publication 20150344850A1 · Dec 3, 2015